Immunome (IMNM) vs Nurix Therapeutics (NRIX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Nurix Therapeutics (NRIX) has outperformed Immunome (IMNM) over the past year, gaining 122.5% versus a gain of 38.2%. Over five years, IMNM leads with a +8.4% price change compared with -23.0% for NRIX. Nurix Therapeutics is the larger company by market cap ($2.30 billion vs $2.28 billion), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMNM | NRIX |
|---|---|---|
| Share price | $19.31 | $22.21 |
| Market cap | $2.28B | $2.30B |
| 1-day change | +1.13% | -2.29% |
| YTD return | -11.10% | +17.08% |
| 1-year return | +38.17% | +122.55% |
| 5-year return | +8.43% | -22.96% |
| EPS (TTM) | $-2.52 | $-3.46 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $30.06 | $28.23 |
| 52-week low | $13.49 | $9.00 |
| Distance from 52-week high | -35.76% | -21.32% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +82.29% | +52.77% |
| Average volume | 1.19M | 1.27M |
| Shares outstanding | 118.00M | 103.78M |
| Employees | 247 | 317 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NRIX has outperformed IMNM by 84.4 percentage points over the past year.
About Immunome
IMNM stock →Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 247 employees
About Nurix Therapeutics
NRIX stock →Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications.
Health Care · Biotechnology: Pharmaceutical Preparations · 317 employees
IMNM vs NRIX FAQ
Which is bigger, Immunome or Nurix Therapeutics?
Nurix Therapeutics (NRIX) is larger, with a market capitalization of $2.30B compared with $2.28B for Immunome (IMNM).
Which stock has performed better over the past year, IMNM or NRIX?
NRIX returned +122.55% over the past 12 months, compared with +38.17% for IMNM (price return, excluding dividends). Past performance does not predict future results.
Are Immunome and Nurix Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.